Doritchamou, Justin http://orcid.org/0000-0002-4589-7216
Nielsen, Morten A.
Chêne, Arnaud
Viebig, Nicola K.
Lambert, Lynn E.
Sander, Adam F.
Semblat, Jean-Philippe
Hundt, Sophia
Orr-Gonzalez, Sachy
Janitzek, Christoph Mikkel
Spiegel, Alicia J.
Clemmensen, Stine B.
Thomas, Marvin L. III
Nason, Martha C.
Snow-Smith, Maryonne
Barnafo, Emma K.
Shiloach, Joseph
Chen, Beth B.
Nadakal, Steven
Highsmith, Kendrick
Ouahes, Tarik
Conteh, Solomon
Sharma, Ankur
Torano, Holly
Butler, Brandi http://orcid.org/0000-0003-2606-4064
Reiter, Karine
Rausch, Kelly M.
Scaria, Puthupparampil V.
Anderson, Charles
Narum, David L.
Salanti, Ali
Fried, Michal
Theander, Thor G.
Gamain, Benoit
Duffy, Patrick E. http://orcid.org/0000-0002-4483-5005
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
EC | Eurostars
Bill and Melinda Gates Foundation (42387 and OPP1055855)
Agence Nationale de la Recherche (ANR-16-CE11-0014-01, ANR-11-IDEX-0005-02, ANR-16-CE11-0014-01, ANR-11-IDEX-0005-02, ANR-16-CE11-0014-01, ANR-11-IDEX-0005-02)
Bundesministerium für Bildung und Forschung (202060457, 202060457)
Irish Aid
Ministry of Higher Education and Science | Forskerakademiet
Article History
Received: 13 September 2022
Accepted: 27 September 2023
First Online: 6 November 2023
Competing interests
: T.G.T. and A. Salanti are named on a patent owned by University of Copenhagen for the use of VAR2CSA as a malaria vaccine. M.A.N., A.F.S., C.M.J., A. Salanti and T.G.T. are named on a patent to use capsid particles in vaccine development. The other authors declare no competing interests.